Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

• Main Authors: Wu Y.-L., Fukuoka M., Mok T.S.K., Saijo N., Thongprasert S., Yang J.C.H., Chu D.-T., Yang J.-J., Rukazenkov Y.
• 格式: Article
• 語言: English
• 出版: 2014
• 在線閱讀: http://www.scopus.com/inward/record.url?eid=2-s2.0-84879884557&partnerID=40&md5=6d90e1b7010d2dea5e5624bd15e89ef8; http://www.ncbi.nlm.nih.gov/pubmed/23540718; http://cmuir.cmu.ac.th/handle/6653943832/4048

Background: In IPASS (NCT00322452), progression-free survival (PFS, primary endpoint) was significantly longer with first-line gefitinib versus carboplatin/paclitaxel in never/light ex-smokers with advanced pulmonary adenocarcinoma in Asia, both in the overall intent-to-treat (ITT) population and in...